Abstract
Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have